Alexander C Flint1, Bin Xiang, Rishi Gupta, Raul G Nogueira, Helmi L Lutsep, Tudor G Jovin, Gregory W Albers, David S Liebeskind, Nerses Sanossian, Wade S Smith. 1. From the Department of Neuroscience, Kaiser Permanente, Redwood City, CA (A.C.F.); Department of Clinical Research, Prospect Analytical, San Jose, CA (B.X.); Departments of Neurology, Neurosurgery, and Radiology, Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA (R.G., R.G.N.); Department of Neurology, Oregon Health and Science University, Portland, OR (H.L.L.); Department of Neurology, UPMC Stroke Center, University of Pittsburgh Medical Center, PA (T.G.J.); Department of Neurology, Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA (G.W.A.); Department of Neurology, UCLA Stroke Center, University of California, Los Angeles, CA (D.S.L.); Department of Neurology, University of Southern California, Los Angeles, CA (N.S.); and Department of Neurology, University of California, San Francisco, CA (W.S.S.).
Abstract
BACKGROUND AND PURPOSE: Several outcome prediction scores have been tested in patients receiving acute stroke treatment with previous generations of endovascular stroke treatment devices. The TREVO-2 trial was a randomized controlled trial comparing a novel endovascular stroke treatment device (the Trevo device) to a previous-generation endovascular stroke treatment device (the Merci device). METHODS: We used data from the TREVO-2 trial to validate the Totaled Health Risks in Vascular Events (THRIVE) score in patients receiving treatment with a third-generation endovascular stroke treatment device and to compare THRIVE to other predictive scores. We used logistic regression to model outcomes and compared score performance with receiver operating characteristic curve analysis. RESULTS: In the TREVO-2 trial, the THRIVE score strongly predicts clinical outcome and mortality. The relationship between THRIVE score and outcome is not influenced by either success of recanalization or the type of device used (Trevo versus Merci). The superiority of the Trevo device to the Merci device is evident particularly among patients with a low-to-moderate THRIVE score (0-5; 53.8% good outcome with Trevo versus 27.5% good outcome with Merci). In receiver operating characteristic curve analysis, the THRIVE score was comparable or superior to several other outcome prediction scores (HIAT, HIAT-2, SPAN-100, and iScore). CONCLUSIONS: The THRIVE score strongly predicts clinical outcome and mortality in the TREVO-2 trial. Taken together with THRIVE validation data from patients receiving intravenous tissue-type plasminogen activator or no acute treatment, the THRIVE score has broad predictive power in patients with acute ischemic stroke, which is likely because THRIVE reflects a set of strong nonmodifiable predictors of stroke outcome. A free Web calculator for the THRIVE score is available at http://www.thrivescore.org.
RCT Entities:
BACKGROUND AND PURPOSE: Several outcome prediction scores have been tested in patients receiving acute stroke treatment with previous generations of endovascular stroke treatment devices. The TREVO-2 trial was a randomized controlled trial comparing a novel endovascular stroke treatment device (the Trevo device) to a previous-generation endovascular stroke treatment device (the Merci device). METHODS: We used data from the TREVO-2 trial to validate the Totaled Health Risks in Vascular Events (THRIVE) score in patients receiving treatment with a third-generation endovascular stroke treatment device and to compare THRIVE to other predictive scores. We used logistic regression to model outcomes and compared score performance with receiver operating characteristic curve analysis. RESULTS: In the TREVO-2 trial, the THRIVE score strongly predicts clinical outcome and mortality. The relationship between THRIVE score and outcome is not influenced by either success of recanalization or the type of device used (Trevo versus Merci). The superiority of the Trevo device to the Merci device is evident particularly among patients with a low-to-moderate THRIVE score (0-5; 53.8% good outcome with Trevo versus 27.5% good outcome with Merci). In receiver operating characteristic curve analysis, the THRIVE score was comparable or superior to several other outcome prediction scores (HIAT, HIAT-2, SPAN-100, and iScore). CONCLUSIONS: The THRIVE score strongly predicts clinical outcome and mortality in the TREVO-2 trial. Taken together with THRIVE validation data from patients receiving intravenous tissue-type plasminogen activator or no acute treatment, the THRIVE score has broad predictive power in patients with acute ischemic stroke, which is likely because THRIVE reflects a set of strong nonmodifiable predictors of stroke outcome. A free Web calculator for the THRIVE score is available at http://www.thrivescore.org.
Authors: Gustavo Saposnik; Jiming Fang; Moira K Kapral; Jack V Tu; Muhammad Mamdani; Peter Austin; S Claiborne Johnston Journal: Stroke Date: 2012-02-03 Impact factor: 7.914
Authors: D Strbian; A Meretoja; F J Ahlhelm; J Pitkäniemi; P Lyrer; M Kaste; S Engelter; T Tatlisumak Journal: Neurology Date: 2012-02-07 Impact factor: 9.910
Authors: Maarten G Lansberg; Matus Straka; Stephanie Kemp; Michael Mlynash; Lawrence R Wechsler; Tudor G Jovin; Michael J Wilder; Helmi L Lutsep; Todd J Czartoski; Richard A Bernstein; Cherylee W J Chang; Steven Warach; Franz Fazekas; Manabu Inoue; Aaryani Tipirneni; Scott A Hamilton; Greg Zaharchuk; Michael P Marks; Roland Bammer; Gregory W Albers Journal: Lancet Neurol Date: 2012-09-04 Impact factor: 44.182
Authors: J H Pexman; P A Barber; M D Hill; R J Sevick; A M Demchuk; M E Hudon; W Y Hu; A M Buchan Journal: AJNR Am J Neuroradiol Date: 2001-09 Impact factor: 3.825
Authors: Raul G Nogueira; Helmi L Lutsep; Rishi Gupta; Tudor G Jovin; Gregory W Albers; Gary A Walker; David S Liebeskind; Wade S Smith Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Alexander C Flint; Hooman Kamel; Vivek A Rao; Sean P Cullen; Bonnie S Faigeles; Wade S Smith Journal: Int J Stroke Date: 2012-08-29 Impact factor: 5.266
Authors: Alexander C Flint; Sean P Cullen; Vivek A Rao; Bonnie S Faigeles; Vitor M Pereira; Elad I Levy; Tudor G Jovin; David S Liebeskind; Raul G Nogueira; Reza Jahan; Jeffrey L Saver Journal: Int J Stroke Date: 2014-05-20 Impact factor: 5.266
Authors: Zhong-Song Shi; David S Liebeskind; Bin Xiang; Sijian Grace Ge; Lei Feng; Gregory W Albers; Ronald Budzik; Thomas Devlin; Rishi Gupta; Olav Jansen; Tudor G Jovin; Monika Killer-Oberpfalzer; Helmi L Lutsep; Juan Macho; Raul G Nogueira; Marilyn Rymer; Wade S Smith; Nils Wahlgren; Gary R Duckwiler Journal: Stroke Date: 2014-05-29 Impact factor: 7.914
Authors: Gustavo W Kuster; Lívia A Dutra; Israel P Brasil; Evelyn P Pacheco; Márcio A C Arruda; Cristiane Volcov; Renan B Domingues Journal: Stroke Res Treat Date: 2014-12-11
Authors: Hisham Salahuddin; Alicia C Castonguay; Syed F Zaidi; Richard Burgess; Ashutosh P Jadhav; Mouhammad A Jumaa Journal: Front Neurol Date: 2020-05-08 Impact factor: 4.003
Authors: Xiaohao Zhang; Kang Yuan; Huaiming Wang; Pengyu Gong; Teng Jiang; Yi Xie; Lei Sheng; Dezhi Liu; Xinfeng Liu; Gelin Xu Journal: J Am Heart Assoc Date: 2020-01-24 Impact factor: 5.501